OBJECTIVETo explore effects of salvianolate on inflammatory cytokines (C-reactive protein, resistin, and adiponectin) of patients with acute coronary syndrome (ACS), and to analyze its possible treatment mechanisms for ACS patients.

METHODSEighty-three inpatients with ACS at the Cardiology Department of our hospital were randomly assigned to the treatment group and the control group from May 2011 to January 2012. Those in the treatment group (42 cases) were treated with routine Western medical treatment and intravenous injection of Salvianolate (200 mg/day), while those in the control group (41 cases) were treated with routine Western medical treatment. The therapeutic course for all was 14 days. The serum levels of resistin,adiponectin, and CRP were observed before and after treatment.

RESULTSCompared with before treatment, the serum levels of resistin and CRP significantly decreased, and the serum level of adiponectin significantly increased in the two groups after treatment (P < 0.05). Besides, the decrement of serum levels of resistin and CRP and the increment of serum adiponectin level were obviously higher in the treatment group than in the control group, showing statistical difference between the two groups (P <0.05).

CONCLUSIONSalvianolate could obviously reduce the serum levels of resistin and CRP, and increase the serum adiponectin lever; indicating that partial therapeutic effects of salvianolate might come from its anti-inflammation.